Original ArticlesClinical Impact of PET Imaging in Patients With Metastatic Prostate CancerTuncel, Murat MD∗; Tuncalı, Meltem Çağlar MD∗; Telli, Tuğçe MD∗; Erman, Mustafa MD†Author Information From the Departments of ∗Nuclear Medicine †Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. Received for publication April 10, 2020; revision accepted April 19, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Murat Tuncel, MD, Department of Nuclear Medicine, Faculty of Medicine, Hacettepe University, 06100 Sıhhiye, Ankara, Turkey. E-mail: email@example.com; firstname.lastname@example.org. Clinical Nuclear Medicine: October 2020 - Volume 45 - Issue 10 - p 757-764 doi: 10.1097/RLU.0000000000003126 Buy Metrics Abstract Prostate cancer (Pca) is the most common cancer and the second leading cause of death among men. Although conventional bone scans and abdominal CT are preferred in most of the guidelines and clinical trials, PET/CT has already started to become the inevitable part of Pca management because of its higher sensitivity and specificity. Radiotracers used for PET imaging show different molecular aspects of the disease process. Although 68Ga–prostate-specific membrane antigen offers the highest sensitivity and specificity, other PET radiotracers such as 18F-FDG and 68Ga-DOTATATE still have a role in patients with prostate-specific membrane antigen–negative diseases such as Pca with neuroendocrine differentiation. In this pictorial essay, we have presented a series of patients with metastatic Pca who had PET images with different radiotracers and discussed the clinical role of this imaging modality in patient management. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.